AXIS BIOSERVICES LIMITED

BT51 3RP (Northern Ireland)

Start Date

End Date Funded Value Relevance

CSV

25 50 100

£307,205

Mar 18 - Aug 21

Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer

Innovate UK award to AXIS BIOSERVICES LIMITED and Jenny Worthington

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}